The place of Zoladex in deferred surgery for uterine fibroids. Zoladex Myoma Study Group.
Two hundred and forty-seven patients with uterine fibroids were randomized to surgery alone or 3 months' Zoladex (Zeneca, Macclesfield, Ches., UK) followed by surgery. Zoladex significantly reduced uterine and fibroid volumes (p = 0.0001). There was a significantly (p = 0.002) greater mean rise in haemoglobin from entry to preoperation in the Zoladex group (1 g/dl) compared with the surgery-alone group (0.3 g/dl) as well as a tendency towards easier surgery, and reduced operative blood loss. Zoladex-treated patients had a significantly (p = 0.016) shorter hospital stay and pelvic pain and abdominal pressure symptoms were significantly (p < 0.0001) reduced in this group. Zoladex was well tolerated.
Gerris
J
J
Department of Obstetries Middelheim Clinic, Antwerp, Belgium.
Degueldre
M
M
Peters
A A
AA
Romao
F
F
Stjernquist
M
M
al-Taher
H
H
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D017273:Goserelin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D007902:Length of Stay; D011292:Premedication; D011446:Prospective Studies; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D014599:Uterus / Q000473:pathology
D018931:Antineoplastic Agents, Hormonal; D006454:Hemoglobins; D017273:Goserelin